Adagene

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Earnings data Q4 2020

- Successful nomination of lead SAFEbody candidates triggers milestone payment -

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

- Posters presented at the 63 rd American Society of Hematology Annual Meeting -

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™

Adagene Inc (NASDAQ: ADAG) announced clinical data on ADG116, and ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021. ADG116 monotherapy in Phase 1 study was well-tolerated up to 6 mg/kg with only mild or moderate treatment-related adverse events (TRAEs) observed; rash (20%) and pruritus (20%) were the most common.

Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial

Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

- Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - - Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab -

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Investigational New Drug (IND) application to proceed with a Phase 1b/2 trial of ADG116, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab).  The global trial (ADG116-P001 / KEYNOTE-C97) will evaluate patients with advanced/metastatic solid tumors at multiple sites in the U.S. and the Asia Pacific (APAC).

Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors

The stock price of Adagene Inc (NASDAQ: ADAG) increased by over 15% pre-market today. This is why it happened.

Adagene (ADAG) Stock: Why The Price Increased Today

ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that members of the company's management will participate virtually in the following investor and industry conferences during November 2021:

Adagene to Participate in Upcoming Investor & Industry Conferences in November

- Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody ™ technology -

Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene's Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual China Biotech Summit to be held October 26, 2021.

Adagene to Participate in the Jefferies Virtual China Biotech Summit

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene's Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will participate in the Morgan Stanley 19th Annual Global Healthcare Conference to be held virtually September 9-15, 2021.

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

- Established three clinical collaborations with Merck to conduct global combination trials  with pembrolizumab for three clinical-stage oncology candidates -

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

Merck

Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.

Adagene Inks Third Cancer Trial Collaboration With Merck

Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

- Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - - Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline -

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  The agreement includes two clinical studies to evaluate Adagene's anti-CTLA-4 monoclonal antibody (mAb) candidates, ADG116 and ADG126, in combination with Merck's Keytruda (pembrolizumab), for patients with advanced/metastatic solid tumors.

Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors

Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic solid tumors Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic solid tumors

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company's insider trading policy.

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) --  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it will be added to the FTSE Global Equity Index Series (“GEIS”), including the FTSE Global Total Cap Index and FTSE Emerging Total Cap Index, effective June 21, 2021.

Adagene Announces Inclusion in FTSE Russell Indexes

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene's Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42nd Annual Global Healthcare Conference to be held June 8-11, 2021.

Adagene to Present at Upcoming Investor Conferences

-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement

News for Adagene Stock (ADAG)